|
1
|
Vande Walle J, Stockner M, Raes A and
Nørgaard JP: Desmopressin 30 years in clinical use: A safety
review. Curr Drug Saf. 2:232–238. 2007. View Article : Google Scholar
|
|
2
|
Manning M, Stoev S, Chini B, Durroux T,
Mouillac B and Guillon G: Peptide and non-peptide agonists and
antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT
receptors: Research tools and potential therapeutic agents. Prog
Brain Res. 170:473–512. 2008.PubMed/NCBI
|
|
3
|
Kaufmann JE and Vischer UM: Cellular
mechanisms of the hemostatic effects of desmopressin (DDAVP). J
Thromb Haemost. 1:682–689. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mannucci PM: Desmopressin (DDAVP) in the
treatment of bleeding disorders: The first 20 years. Blood.
90:2515–2521. 1997.PubMed/NCBI
|
|
5
|
Manning M, Misicka A, Olma A, Bankowski K,
Stoev S, Chini B, Durroux T, Mouillac B, Corbani M and Guillon G:
Oxytocin and vasopressin agonists and antagonists as research tools
and potential therapeutics. J Neuroendocrinol. 24:609–628. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
North WG, Fay MJ and Du J: MCF-7 breast
cancer cells express normal forms of all vasopressin receptors plus
an abnormal V2R. Peptides. 20:837–842. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petit T, Davidson KK, Lawrence RA, von
Hoff DD and Izbicka E: Neuropeptide receptor status in human tumor
cell lines. Anticancer Drugs. 12:133–136. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taylor AH, Ang VT, Jenkins JS, Silverlight
JJ, Coombes RC and Luqmani YA: Interaction of vasopressin and
oxytocin with human breast carcinoma cells. Cancer Res.
50:7882–7886. 1990.PubMed/NCBI
|
|
9
|
Alonso DF, Skilton G, Farías EF, Bal de
Kier Joffé E and Gomez DE: Antimetastatic effect of desmopressin in
a mouse mammary tumor model. Breast Cancer Res Treat. 57:271–275.
1999. View Article : Google Scholar
|
|
10
|
Garona J, Pifano M, Scursoni AM, Gomez DE,
Alonso DF and Ripoll GV: Insight into the effect of the vasopressin
analog desmopressin on lung colonization by mammary carcinoma cells
in BALB/c mice. Anticancer Res. 34:4761–4765. 2014.PubMed/NCBI
|
|
11
|
Giron S, Tejera AM, Ripoll GV, Gomez DE
and Alonso DF: Desmopressin inhibits lung and lymph node metastasis
in a mouse mammary carcinoma model of surgical manipulation. J Surg
Oncol. 81:38–44. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hermo GA, Torres P, Ripoll GV, Scursoni
AM, Gomez DE, Alonso DF and Gobello C: Perioperative desmopressin
prolongs survival in surgically treated bitches with mammary gland
tumours: A pilot study. Vet J. 178:103–108. 2008. View Article : Google Scholar
|
|
13
|
Hermo GA, Turic E, Angelico D, Scursoni
AM, Gomez DE, Gobello C and Alonso DF: Effect of adjuvant
perioperative desmopressin in locally advanced canine mammary
carcinoma and its relation to histologic grade. J Am Anim Hosp
Assoc. 47:21–27. 2011. View Article : Google Scholar
|
|
14
|
Terraube V, Pendu R, Baruch D, Gebbink MF,
Meyer D, Lenting PJ and Denis CV: Increased metastatic potential of
tumor cells in von Willebrand factor-deficient mice. J Thromb
Haemost. 4:519–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ripoll GV, Garona J, Pifano M, Farina HG,
Gomez DE and Alonso DF: Reduction of tumor angiogenesis induced by
desmopressin in a breast cancer model. Breast Cancer Res Treat.
142:9–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakurai T and Kudo M: Signaling pathways
governing tumor angiogenesis. Oncology. 81(Suppl 1): 24–29. 2011.
View Article : Google Scholar
|
|
17
|
Westphal JR, Van’t Hullenaar R,
Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, Askaa J,
Clemmensen I, Eggermont AA, Ruiter DJ, et al: Angiostatin
generation by human tumor cell lines: involvement of plasminogen
activators. Int J Cancer. 86:760–767. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alonso DF, Ripoll GV, Garona J, Iannucci
NB and Gomez DE: Metastasis: Recent discoveries and novel
perioperative treatment strategies with particular interest in the
hemostatic compound desmopressin. Curr Pharm Biotechnol.
12:1974–1980. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Czaplewski C, Kaźmierkiewicz R and
Ciarkowski J: Molecular modeling of the human vasopressin V2
receptor/agonist complex. J Comput Aided Mol Des. 12:275–287. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Czaplewski C, Kaźmierkiewicz R and
Ciarkowski J: Molecular modelling of the vasopressin V2
receptor/antagonist interactions. Acta Biochim Pol. 45:19–26.
1998.PubMed/NCBI
|
|
21
|
Iannucci NB, Ripoll GV, Garona J, Cascone
O, Ciccia GN, Gomez DE and Alonso DF: Antiproliferative effect of
1-deamino-8-D-arginine vasopressin analogs on human breast cancer
cells. Future Med Chem. 3:1987–1993. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pastrian MB, Guzmán F, Garona J, Pifano M,
Ripoll GV, Cascone O, Ciccia GN, Albericio F, Gómez DE, Alonso DF,
et al: Structure-activity relationship of 1-desamino-8-D-arginine
vasopressin as an antiproliferative agent on human vasopressin V2
receptor-expressing cancer cells. Mol Med Rep. 9:2568–2572.
2014.PubMed/NCBI
|
|
23
|
Holliday DL and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ripoll GV, Giron S, Krzymuski MJ, Hermo
GA, Gomez DE and Alonso DF: Antitumor effects of desmopressin in
combination with chemotherapeutic agents in a mouse model of breast
cancer. Anticancer Res. 28A:2607–2611. 2008.
|
|
25
|
Cardama GA, Comin MJ, Hornos L, Gonzalez
N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE and Menna PL:
Preclinical development of novel Rac1-GEF signaling inhibitors
using a rational design approach in highly aggressive breast cancer
cell lines. Anticancer Agents Med Chem. 14:840–851. 2014.
View Article : Google Scholar :
|
|
26
|
Jones LW, Eves ND, Courneya KS, Chiu BK,
Baracos VE, Hanson J, Johnson L and Mackey JR: Effects of exercise
training on antitumor efficacy of doxorubicin in MDA-MB-231 breast
cancer xenografts. Clin Cancer Res. 11:6695–6698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaufmann JE, Oksche A, Wollheim CB,
Günther G, Rosenthal W and Vischer UM: Vasopressin-induced von
Willebrand factor secretion from endothelial cells involves V2
receptors and cAMP. J Clin Invest. 106:107–116. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han SS, Cho CK, Lee YW and Yoo HS:
Antimetastatic and immunomodulating effect of water extracts from
various mushrooms. J Acupunct Meridian Stud. 2:218–227. 2009.
View Article : Google Scholar
|
|
29
|
North WG, Pai S, Friedmann A, Yu X, Fay M
and Memoli V: Vasopressin gene related products are markers of
human breast cancer. Breast Cancer Res Treat. 34:229–235. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Keegan BP, Akerman BL, Péqueux C and North
WG: Provasopressin expression by breast cancer cells: Implications
for growth and novel treatment strategies. Breast Cancer Res Treat.
95:265–277. 2006. View Article : Google Scholar
|
|
31
|
Carie AE and Sebti SM: A chemical biology
approach identifies a beta-2 adrenergic receptor agonist that
causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2
pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Insel PA, Zhang L, Murray F, Yokouchi H
and Zambon AC: Cyclic AMP is both a pro-apoptotic and
anti-apoptotic second messenger. Acta Physiol (Oxf). 204:277–287.
2012. View Article : Google Scholar
|
|
33
|
Naviglio S, Di Gesto D, Romano M,
Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M,
Caraglia M, Chiosi E, et al: Leptin enhances growth inhibition by
cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer
cells. Cancer Biol Ther. 8:1183–1190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Castoria G, Migliaccio A, D’Amato L, Di
Stasio R, Ciociola A, Lombardi M, Bilancio A, Di Domenico M, De
Falco A and Auricchio F: Integrating signals between cAMP and MAPK
pathways in breast cancer. Front Biosci. 13:1318–1327. 2008.
View Article : Google Scholar
|
|
35
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer--current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bayraktar S and Glück S: Molecularly
targeted therapies for metastatic triple-negative breast cancer.
Breast Cancer Res Treat. 138:21–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Terrenato I, Arena V, Pizzamiglio S,
Pennacchia I, Perracchio L, Buglioni S, Ercolani C, Sperati F,
Costarelli L, Bonanno E, et al: External Quality Assessment (EQA)
program for the preanalytical and analytical immunohistochemical
determination of HER2 in breast cancer: An experience on a regional
scale. J Exp Clin Cancer Res. 32:582013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gangloff A, Hsueh WA, Kesner AL,
Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J,
Phelps ME, et al: Estimation of paclitaxel biodistribution and
uptake in human-derived xenografts in vivo with
(18)F-fluoropaclitaxel. J Nucl Med. 46:1866–1871. 2005.PubMed/NCBI
|
|
39
|
Ripoll G, Iannucci N, Giron S, Cascone O,
Gomez D and Alonso D: Angiostatic activity of
1-Deamino-8-D-Arginine vasopressin and novel peptide analogues in
breast cancer cells. Proc AACR Abst. 295:2008.
|
|
40
|
Huang J, Roth R, Heuser JE and Sadler JE:
Integrin alpha(v) beta(3) on human endothelial cells binds von
Willebrand factor strings under fluid shear stress. Blood.
113:1589–1597. 2009. View Article : Google Scholar :
|
|
41
|
Starke RD, Ferraro F, Paschalaki KE,
Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD,
Cutler DF, et al: Endothelial von Willebrand factor regulates
angiogenesis. Blood. 117:1071–1080. 2011. View Article : Google Scholar :
|
|
42
|
Howe AK: Regulation of actin-based cell
migration by cAMP/ PKA. Biochim Biophys Acta. 1692:159–174. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Howe AK, Baldor LC and Hogan BP: Spatial
regulation of the cAMP-dependent protein kinase during chemotactic
cell migration. Proc Natl Acad Sci USA. 102:14320–14325. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim S, Harris M and Varner JA: Regulation
of integrin alpha vbeta 3-mediated endothelial cell migration and
angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol
Chem. 275:33920–33928. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Terraube V, Marx I and Denis CV: Role of
von Willebrand factor in tumor metastasis. Thromb Res. 120(Suppl
2): S64–S70. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mochizuki S, Soejima K, Shimoda M, Abe H,
Sasaki A, Okano HJ, Okano H and Okada Y: Effect of ADAM28 on
carcinoma cell metastasis by cleavage of von Willebrand factor. J
Natl Cancer Inst. 104:906–922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Erdélyi LS, Balla A, Patócs A, Tóth M,
Várnai P and Hunyady L: Altered agonist sensitivity of a mutant v2
receptor suggests a novel therapeutic strategy for nephrogenic
diabetes insipidus. Mol Endocrinol. 28:634–643. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu H, Gaza-Bulseco G and Chumsae C:
Glutamine deamidation of a recombinant monoclonal antibody. Rapid
Commun Mass Spectrom. 22:4081–4088. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Robinson AB and Rudd CJ: Deamidation of
glutaminyl and asparaginyl residues in peptides and proteins. Curr
Top Cell Regul. 8:247–295. 1974.PubMed/NCBI
|
|
50
|
Lianos GD, Vlachos K, Zoras O, Katsios C,
Cho WC and Roukos DH: Potential of antibody-drug conjugates and
novel therapeutics in breast cancer management. Onco Targets Ther.
7:491–500. 2014.PubMed/NCBI
|
|
51
|
Bacic I, Druzijanic N, Karlo R, Skific I
and Jagic S: Efficacy of IP6 inositol in the treatment of breast
cancer patients receiving chemotherapy: Prospective, randomized,
pilot clinical study. J Exp Clin Cancer Res. 29:122010. View Article : Google Scholar
|
|
52
|
Fabbrocini G, Cameli N, Romano MC, Mariano
M, Panariello L, Bianca D and Monfrecola G: Chemotherapy and skin
reactions. J Exp Clin Cancer Res. 31:502012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang S, Noberini R, Stebbins JL, Das S,
Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, et al:
Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
Clin Cancer Res. 19:128–137. 2013. View Article : Google Scholar :
|
